Olema Pharmaceuticals(US:OLMA) Financial Modeling Prep·2026-03-09 23:25Core Viewpoint - Olema Pharmaceuticals Inc. is focused on developing targeted therapies for women's cancers, particularly breast cancer, with its leading project being Palazestrant, a new class of treatments [1][4] Company Overview - Olema Pharmaceuticals Inc. is a biopharmaceutical company dedicated to women's cancer therapies, with strategic collaborations with pharmaceutical giants like Pfizer Inc. and Novartis AG [1][4] - The company's leading project, Palazestrant, is a complete estrogen receptor antagonist and selective estrogen receptor degrader [1] Stock Performance - On March 9, 2026, H.C. Wainwright set a price target of $38 for Olema, indicating a potential upside of approximately 69% from a trading price of $16.45 [2] - The stock has recently declined to $16.30, marking a decrease of 24.36% from its previous price, attributed to disappointing results from Roche Holdings AG's phase 3 study [2] - Olema's stock has shown significant volatility, with a trading range over the past year between $2.86 and $36.26, and a market capitalization of approximately $1.28 billion [3][4]